Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BMT for Marrow Failure States
NCT00005852Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 1996
- Primary completion
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, muromonab-CD3 in aplastic anemia, Graft failure, sponsored by Moffitt Cancer Center. Started Jun 1996; status: terminated.
02
Drugs
antithymocyte globulin rabbitmuromonab-CD3
03
Conditions
aplastic anemiaGraft failure
Beyond the preview
Go deeper on NCT00005852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005852.